Advertisement

Clinical and Experimental Nephrology

, Volume 19, Issue 1, pp 34–53 | Cite as

Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: general therapy

  • Yoshitsugu Kaku
  • Yasufumi Ohtsuka
  • Yasuhiro Komatsu
  • Toshiyuki Ohta
  • Takuhito Nagai
  • Hiroshi Kaito
  • Shuji Kondo
  • Yohei Ikezumi
  • Seiji Tanaka
  • Shinsuke Matsumoto
  • Mayumi Sako
  • Kazushi Tsuruga
  • Koichi Nakanishi
  • Koichi Kamei
  • Hiroshi Saito
  • Shuichiro Fujinaga
  • Yuko Hamasaki
  • Hiroko Chikamoto
  • Kenji IshikuraEmail author
  • Kazumoto Iijima
Guideline

Introduction

Pediatric idiopathic nephrotic syndrome is a very important disease in the field of pediatric nephrology. The Japanese Society for Pediatric Nephrology published the “Clinical Practice Guideline for Medical Treatment of Pediatric Idiopathic Nephrotic Syndrome (version 1.0) (in Japanese)” in 2005. The guideline, aiming to support appropriate decision and treatment for pediatric idiopathic nephrotic syndrome, illustrated standard regimens of medical treatment of pediatric idiopathic nephrotic syndrome at that time and has been credited with standardization and optimization of the treatment. In 2011, 6 years after the publication, the need to revise the guideline became recognized against the background of changes in care setting including introduction of rituximab. Additionally, development of guideline covering general therapies was required.

The Scientific Committee of the Japanese Society for Pediatric Nephrology established a new operation to revise the guideline and...

Keywords

Bone Mineral Density Nephrotic Syndrome Idiopathic Nephrotic Syndrome Sodium Restriction Growth Deficiency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The development of this guideline was solely supported by the society budget of the Japanese Society for Pediatric Nephrology. All members engaged in the guideline development submitted Conflicts of Interest declaration forms, which are retained by the Japanese Society for Pediatric Nephrology. To avoid the influence of any conflicts of interest on the contents of this guideline, discussions were made in an open manner using a mailing list system. Opinions of multiple reviewers (councilor board members of the Japanese Society for Pediatric Nephrology and an epidemiologist as an outside reviewer) and public comments were used to refine the guideline.

Kazumoto Iijima, Yoshitsugu Kaku, and  Kenji Ishikura played an essential role in scientific discussion and preparation and review of the manuscript. The rest of the authors all contributed equally to the work. The authors thank for the contribution of Ms. Fujimi Kawai and Ms. Satomi Kojima, The Japan Medical Library Association, for expert consultation on the development of the guideline; Mr. Kyoshiro Yanagisawa and Ms. Yumi Yanagisawa for advice from a viewpoint of a patient and its guardian; Dr. Kaori Kikunaga, Tokyo Metropolitan Children’s Medical Center, for clerical and coordination duties; ASCA Corporation for translation and editorial supports in the preparation of the manuscript; and Dr. Noriko Kojimahara, Tokyo Women’s Medical University, Dr. Shuichi Ito, the National Center for Child Health and Development, and Dr. Shoji Kagami, the University of Tokushima, for proper and thorough review of the guideline.

References

  1. 1.
    Ishikura K, Matsumoto S, Sako M, Tsuruga K, Nakanishi K, Kamei K, Saito H, Fujinaga S, Hamasaki Y, Chikamoto H, Ohtsuka Y, Komatsu Y, Ohta T, Nagai T, Kaito H, Kondo S, Ikezumi Y, Tanaka S, Kaku Y, Iijima K. Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy, clinical and experimental nephrology. doi: 10.1007/s10157-014-1030-x.
  2. 2.
    Gipson DS, Massengill SF, Yao L, Nagaraj S, Smoyer WE, Mahan JD, Wigfall D, Miles P, Powell L, Lin JJ, Trachtman H, Greenbaum LA. Management of childhood onset nephrotic syndrome. Pediatrics. 2009;124(2):747–57.CrossRefPubMedGoogle Scholar
  3. 3.
    Indian Pediatric Nephrology Group, Indian Academy of Pediatrics, Bagga A, Ali U, Banerjee S, Kanitkar M, Phadke KD, Senguttuvan P, Sethi S, Shah M. Management of steroid sensitive nephrotic syndrome: revised guidelines. Indian Pediatr. 2008;45(3):203–14.Google Scholar
  4. 4.
    Vasudevan A, Mantan M, Bagga A. Management of edema in nephrotic syndrome. Indian Pediatr. 2004;41(8):787–95.PubMedGoogle Scholar
  5. 5.
    Park SJ, Shin JI. Complications of nephrotic syndrome. Korean J Pediatr. 2011;54(8):322–8.CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Doucet A, Favre G, Deschênes G. Molecular mechanism of edema formation in nephrotic syndrome: therapeutic implications. Pediatr Nephrol. 2007;22(12):1983–90.CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Siddall EC, Radhakrishnan J. The pathophysiology of edema formation in the nephrotic syndrome. Kidney Int. 2012;82(6):635–42.CrossRefPubMedGoogle Scholar
  8. 8.
    Avner ED, Harmon WE, Niaudet P, Yoshikawa N, editors. Pediatric nephrology. 6th ed. Baltimore: Lippincott Williams and Wilkins; 2009.Google Scholar
  9. 9.
    Vande Walle JG, Donckerwolcke RA, van Isselt JW, Derkx FH, Joles JA, Koomans HA. Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovolaemic symptoms. Lancet. 1995;15:148–52.Google Scholar
  10. 10.
    Wang SJ, Tsau YK, Lu FL, Chen CH. Hypovolemia and hypovolemic shock in children with nephrotic syndrome. Acta Paediatr Taiwan. 2000;41:179–83.PubMedGoogle Scholar
  11. 11.
    Vande Walle JG, Donckerwolcke RA, Koomans HA. Pathophysiology of edema formation in children with nephrotic syndrome not due to minimal change disease. J Am Soc Nephrol. 1999;10:323–31.PubMedGoogle Scholar
  12. 12.
    Van de Walle JG, Donckerwolcke RA, Greidanus TB, Joles JA, Koomans HA. Renal sodium handling in children with nephrotic relapse: relation to hypovolaemic symptoms. Nephrol Dial Transplant. 1996;11:2202–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Reid CJ, Marsh MJ, Murdoch IM, Clark G. Nephrotic syndrome in childhood complicated by life threatening pulmonary oedema. BMJ. 1996;312:36–8.CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Haws RM, Baum M. Efficacy of albumin and diuretic therapy in children with nephrotic syndrome. Pediatrics. 1993;91:1142–6.PubMedGoogle Scholar
  15. 15.
    Agarwal N, Phadke KD, Garg I, Alexander P. Acute renal failure in children with idiopathic nephrotic syndrome. Pediatr Nephrol. 2003;18:1289–92.CrossRefPubMedGoogle Scholar
  16. 16.
    Loghman-Adham M, Siegler RL, Pysher TJ. Acute renal failure in idiopathic nephrotic syndrome. Clin Nephrol. 1997;47:76–80.PubMedGoogle Scholar
  17. 17.
    Sakarcan A, Timmons C, Seikaly MG. Reversible idiopathic acute renal failure in children with primary nephrotic syndrome. J Pediatr. 1994;125(5 Pt 1):723–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Gurgoze MK, Gunduz Z, Poyrazoglu MH, Dursun I, Uzum K, Dusunsel R. Role of sodium during formation of edema in children with nephrotic syndrome. Pediatr Int. 2011;53:50–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Dönmez O, Mir S, Ozyürek R, Cura A, Kabasakal C. Inferior vena cava indices determine volume load in minimal lesion nephrotic syndrome. Pediatr Nephrol. 2001;16:251–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Tabel Y, Mungan I, Karakurt C, Kocak G, Gungor S. Is edema in minimal change disease of childhood really hypovolemic? Int Urol Nephrol. 2008;40:757–61.CrossRefPubMedGoogle Scholar
  21. 21.
    Donckerwolcke RA, France A, Raes A, Vande Walle J. Distal nephron sodium–potassium exchange in children with nephrotic syndrome. Clin Nephrol. 2003;59:259–66.CrossRefPubMedGoogle Scholar
  22. 22.
    Kapur G, Valentini RP, Imam AA, Jain A, Mattoo TK. Serum osmolal gap in patients with idiopathic nephrotic syndrome and severe edema. Pediatrics. 2007;119(6):e1404–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Bozzetto S, Piccoli A, Montini G. Bioelectrical impedance vector analysis to evaluate relative hydration status. Pediatr Nephrol. 2010;25:329–34.CrossRefPubMedGoogle Scholar
  24. 24.
    van der Vorst MM, Kist JE, van der Heijden AJ, Burggraaf J. Diuretics in pediatrics: current knowledge and future prospects. Paediatr Drugs. 2006;8(4):245–64.CrossRefPubMedGoogle Scholar
  25. 25.
    Eades SK, Christensen ML. The clinical pharmacology of loop diuretics in the pediatric patient. Pediatr Nephrol. 1998;12(7):603–16.CrossRefPubMedGoogle Scholar
  26. 26.
    Prandota J. Pharmacokinetics of furosemide urinary elimination by nephrotic children. Pediatr Res. 1983;17(2):141–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Brater DC. Diuretic therapy. N Engl J Med. 1998;339(6):387–95.CrossRefPubMedGoogle Scholar
  28. 28.
    Garin EH. A comparison of combinations of diuretics in nephrotic edema. Am J Dis Child. 1987;141:769–71.PubMedGoogle Scholar
  29. 29.
    Kapur G, Valentini RP, Imam AA, Mattoo TK. Treatment of severe edema in children with nephrotic syndrome with diuretics alone—a prospective study. Clin J Am Soc Nephrol. 2009;4:907–13.CrossRefPubMedCentralPubMedGoogle Scholar
  30. 30.
    Dharmaraj R, Hari P, Bagga A. Randomized cross-over trial comparing albumin and frusemide infusions in nephrotic syndrome. Pediatr Nephrol. 2009;24:775–82.CrossRefPubMedGoogle Scholar
  31. 31.
    Lewis MA, Awan A. Mannitol and frusemide in the treatment of diuretic resistant oedema in nephrotic syndrome. Arch Dis Child. 1999;80:184–5.CrossRefPubMedCentralPubMedGoogle Scholar
  32. 32.
    Kanzaki M, Wada J, Kikumoto Y, Akagi S, Nakao K, Sugiyama H, Makino H. The therapeutic potential of synthetic human atrial natriuretic peptide in nephrotic syndrome: a randomized controlled trial. Int J Nephrol Renovasc Dis. 2012;5:91–6.PubMedCentralPubMedGoogle Scholar
  33. 33.
    Bircan Z, Kervancioğlu M, Katar S, Vitrinel A. Does albumin and furosemide therapy affect plasma volume in nephrotic children? Pediatr Nephrol. 2001;16:497–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Fauchald P, Noddeland H, Norseth J. An evaluation of ultrafiltration as treatment of diuretic-resistant oedema in nephrotic syndrome. Acta Med Scand. 1985;217:127–31.CrossRefPubMedGoogle Scholar
  35. 35.
    Kaysen GA, Gambertoglio J, Jimenez I, Jones H, Hutchison FN. Effect of dietary protein intake on albumin homeostasis in nephrotic patients. Kidney Int. 1986;29:572–7.CrossRefPubMedGoogle Scholar
  36. 36.
    Rosenberg ME, Swanson JE, Thomas BL, Hostetter TH. Glomerular and hormonal responses to dietary protein intake in human renal disease. Am J Physiol 1987;253 F1083–F1090.Google Scholar
  37. 37.
    Poortmans JR, Vanderstraeten J. Kidney function during exercise in healthy and diseased humans. An update. Sports Med. 1994;18:419–37.CrossRefPubMedGoogle Scholar
  38. 38.
    Nagasaka Y, Yogi S, Taguchi H, Yoshida Y, Fujiwara Y. Participation to swimming lessons and relapse of nephrotic syndrome [in Japanese]. J Jpn Pediatr Soc. 1986;90:2737–41.Google Scholar
  39. 39.
    Nagasaka Y. The effect of swimming on renal function in children with renal disease [in Japanese]. Jpn J Nephrol. 1986;28:1465–70.Google Scholar
  40. 40.
    Miura H, Fukui H, Hayano K, Otsuka Y, Hattori S. A case of minimal change nephrotic syndrome associated with acute renal failure after excessive exercise. Nihon Jinzo Gakkai Shi. 1993;35:387–91.PubMedGoogle Scholar
  41. 41.
    Kayali F, Najjar R, Aswad F, Matta F, Stein PD. Venous thromboembolism in patients hospitalized with nephrotic syndrome. Am J Med. 2008;121(3):226–30.CrossRefPubMedGoogle Scholar
  42. 42.
    Hoyer PF, Gonda S, Barthels M, Krohn HP, Brodehl J. Thromboembolic complications in children with nephrotic syndrome. Risk and incidence. Acta Paediatr Scand. 1986;75:804–10.CrossRefPubMedGoogle Scholar
  43. 43.
    Kerlin BA, Blatt NB, Fuh B, Zhao S, Lehman A, Blanchong C, Mahan JD, Smoyer WE. Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) Study. J Pediatr. 2009;155:105–10.CrossRefPubMedCentralPubMedGoogle Scholar
  44. 44.
    Lilova MI, Velkovski IG, Topalov IB. Thromboembolic complications in children with nephrotic syndrome in Bulgaria (1974–1996). Pediatr Nephrol. 2000;15:74–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Hegarty J, Mughal MZ, Adams J, Webb NJ. Reduced bone mineral density in adults treated with high-dose corticosteroids for childhood nephrotic syndrome. Kidney Int. 2005;68:2304–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Foster BJ, Shults J, Zemel BS, Leonard MB. Risk factors for glucocorticoid-induced obesity in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2006;21:973–80.CrossRefPubMedGoogle Scholar
  47. 47.
    Merritt RJ, Hack SL, Kalsch M, Olson D. Corticosteroid therapy-induced obesity in children. Clin Pediatr (Phila). 1986;25:149–52.CrossRefGoogle Scholar
  48. 48.
    Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350:2362–74.CrossRefPubMedGoogle Scholar
  49. 49.
    Savoye M, Shaw M, Dziura J, Tamborlane WV, Rose P, Guandalini C, Goldberg-Gell R, Burgert TS, Cali AM, Weiss R, Caprio S. Effects of a weight management program on body composition and metabolic parameters in overweight children: a randomized controlled trial. JAMA. 2007;297:2697–704.CrossRefPubMedGoogle Scholar
  50. 50.
    Goto M, Ninomiya M, Uemura O, Matsuyama K, Ito Y, Hataya H, Ito S, Yamakawa S, Ishikawa T, Honda M. A questionnaire survey on exercise limitation in children with kidney disease [in Japanese]. Jpn J Pediatr Nephrol. 2012;25(6):17.Google Scholar
  51. 51.
    van Staa TP, Cooper C, Leufkens HG, Bishop N. Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res. 2003;18(5):913–8.CrossRefPubMedGoogle Scholar
  52. 52.
    Leonard MB, Feldman HI, Shults J, Zemel BS, Foster BJ, Stallings VA. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med. 2004;351:868–75.CrossRefPubMedGoogle Scholar
  53. 53.
    Freundlich M, Jofe M, Goodman WG, Salusky IB. Bone histology in steroid-treated children with non-azotemic nephrotic syndrome. Pediatr Nephrol. 2004;19:400–7.CrossRefPubMedGoogle Scholar
  54. 54.
    Reyes ML, Hernández MI, King A, Vinet AM, Vogel A, Lagomarsino E, Mericq MV, Méndez C, Gederlini A, Talesnik E. Corticosteroid-induced osteoporosis in children: outcome after two-year follow-up, risk factors, densitometric predictive cut-off values for vertebral fractures. Clin Exp Rheumatol. 2007;25:329–35.PubMedGoogle Scholar
  55. 55.
    Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford). 2005;44(6):813–8.CrossRefGoogle Scholar
  56. 56.
    Bak M, Serdaroglu E, Guclu R. Prophylactic calcium and vitamin D treatments in steroid-treated children with nephrotic syndrome. Pediatr Nephrol. 2006;21:350–4.CrossRefPubMedGoogle Scholar
  57. 57.
    Kaiser BA, Polinsky MS, Palmer JA, Dunn S, Mochon M, Flynn JT, Baluarte HJ. Growth after conversion to alternate-day corticosteroids in children with renal transplants: a single-center study. Pediatr Nephrol. 1994;8:320–5.CrossRefPubMedGoogle Scholar
  58. 58.
    Broyer M, Guest G, Gagnadoux MF. Growth rate in children receiving alternate-day corticosteroid treatment after kidney transplantation. J Pediatr. 1992;120:721–5.CrossRefPubMedGoogle Scholar
  59. 59.
    Guest G, Broyer M. Growth after renal transplantation: correlation with immunosuppressive therapy. Pediatr Nephrol. 1991;5:143–6.CrossRefPubMedGoogle Scholar
  60. 60.
    Hokken-Koelega AC, Van Zaal MA, de Ridder MA, Wolff ED, De Jong MC, Donckerwolcke RA, De Muinck Keizer-Schrama SM, Drop SL. Growth after renal transplantation in prepubertal children: impact of various treatment modalities. Pediatr Res. 1994;35:367–71.CrossRefPubMedGoogle Scholar
  61. 61.
    Jabs K, Sullivan EK, Avner ED, Harmon WE. Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. A report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation. 1996;61:31.CrossRefPubMedGoogle Scholar
  62. 62.
    Yamashita F, Funatsu T, Nagayama K, Arihiro H, Anan S. Evaluation of alternate-day steroid therapy for nephrotic syndrome in childhood by cross-over study. Kurume Med J. 1971;18:153–60.CrossRefPubMedGoogle Scholar
  63. 63.
    Kimura Y, Fieldston E, Devries-Vandervlugt B, Li S, Imundo L. High dose, alternate day corticosteroids for systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2000;27:2018–24.PubMedGoogle Scholar
  64. 64.
    Simmonds J, Trompeter R, Tullus K. Long-term steroid treatment and growth: a study in steroid-dependent nephrotic syndrome. Arch Dis Child. 2010;95:146–9.CrossRefPubMedGoogle Scholar
  65. 65.
    Rivkees SA, Danon M, Herrin J. Prednisone dose limitation of growth hormone treatment of steroid-induced growth failure. J Pediatr. 1994;125:322–5.Google Scholar
  66. 66.
    Bachmann HJ, Schildberg P, Olbing H, Krämer D, Waubke T. Cortisone cataract in children with nephrotic syndrome. Eur J Pediatr. 1977;124:277–83.CrossRefPubMedGoogle Scholar
  67. 67.
    Brocklebank JT, Harcourt RB, Meadow SR. Corticosteroid-induced cataracts in idiopathic nephrotic syndrome. Arch Dis Child. 1982;57:30–4.PubMedCentralPubMedGoogle Scholar
  68. 68.
    Forman AR, Loreto JA, Tina LU. Reversibility of corticosteroid-associated cataracts in children with the nephrotic syndrome. Am J Ophthalmol. 1977;84:75–8.CrossRefPubMedGoogle Scholar
  69. 69.
    Limaye SR, Pillai S, Tina LU. Relationship of steroid dose to degree of posterior subcapsular cataracts in nephrotic syndrome. Ann Ophthalmol. 1988;20:225–7.PubMedGoogle Scholar
  70. 70.
    Kobayashi Y, Akaishi K, Nishio T, Kobayashi Y, Kimura Y. Posterior subcapsular cataract in nephrotic children receiving steroid therapy. Am J Dis Child. 1974;128:671–3.PubMedGoogle Scholar
  71. 71.
    Hayasaka Y, Hayasaka S, Matsukura H. Ocular findings in Japanese children with nephrotic syndrome receiving prolonged corticosteroid therapy. Ophthalmologica. 2006;220:181–5.CrossRefPubMedGoogle Scholar
  72. 72.
    Kaye LD, Kalenak JW, Price RL, Cunningham R. Ocular implications of long-term prednisone therapy in children. J Pediatr Ophthalmol Strabismus. 1993;30:142–4.Google Scholar
  73. 73.
    Ng JS, Wong W, Law RW, Hui J, Wong EN, Lam DS. Ocular complications of paediatric patients with nephrotic syndrome. Clin Exp Ophthalmol. 2001;29:239–43.CrossRefGoogle Scholar
  74. 74.
    Chen CH, Chen CM. Lee PP. The effect of betamethasone on intraocular pressure in nephrotic children. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1994;35:197–201.PubMedGoogle Scholar
  75. 75.
    Alwadhi RK, Mathew JL, Rath B. Clinical profile of children with nephrotic syndrome not on glucorticoid therapy, but presenting with infection. J Paediatr Child Health. 2004;40:28–32.CrossRefPubMedGoogle Scholar
  76. 76.
    Dowell SF, Bresee JS. Severe varicella associated with steroid use. Pediatrics. 1993;92:223–8.PubMedGoogle Scholar
  77. 77.
    Uncu N, Bülbül M, Yildiz N, Noyan A, Koşan C, Kavukçu S, Calişkan S, Gündüz Z, Beşbaş N. Gür Güven A. Primary peritonitis in children with nephrotic syndrome: results of a 5-year multicenter study. Eur J Pediatr. 2010;169:73–6.CrossRefPubMedGoogle Scholar
  78. 78.
    Tain YL, Lin G, Cher TW. Microbiological spectrum of septicemia and peritonitis in nephrotic children. Pediatr Nephrol. 1999;13:835–7.CrossRefPubMedGoogle Scholar
  79. 79.
    Hsu K, Pelton S, Karumuri S, Heisey-Grove D, Klein J. Massachusetts Department of Public Health Epidemiologists. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr Infect Dis J. 2005;24:17–23.CrossRefPubMedGoogle Scholar
  80. 80.
    Ulinski T, Leroy S, Dubrel M, Danon S, Bensman A. High serological response to pneumococcal vaccine in nephrotic children at disease onset on high-dose prednisone. Pediatr Nephrol. 2008;23:1107–13.CrossRefPubMedGoogle Scholar
  81. 81.
    Aoun B, Wannous H, Azéma C, Ulinski T. Polysaccharide pneumococcal vaccination of nephrotic children at disease onset-long-term data. Pediatr Nephrol. 2010;25:1773–4.CrossRefPubMedGoogle Scholar
  82. 82.
    Liakou CD, Askiti V, Mitsioni A, Stefanidis CJ, Theodoridou MC, Spoulou VI. Safety, immunogenicity and kinetics of immune response to 7-valent pneumococcal conjugate vaccine in children with idiopathic nephrotic syndrome. Vaccine. 2011;16(29):6834–7.CrossRefGoogle Scholar
  83. 83.
    Poyrazoğlu HM, Düşünsel R, Gündüz Z, Patiroğlu T, Köklü S. Antibody response to influenza A vaccination in children with nephrotic syndrome. Pediatr Nephrol. 2004;19:57–60.CrossRefPubMedGoogle Scholar
  84. 84.
    Laube GF, Berger C, Goetschel P, Leumann E, Neuhaus TJ. Immunization in children with chronic renal failure. Pediatr Nephrol. 2002;17:638–42.CrossRefPubMedGoogle Scholar
  85. 85.
    Furth SL, Arbus GS, Hogg R, Tarver J, Chan C, Fivush BA, Southwest Pediatric Nephrology Study Group. Varicella vaccination in children with nephrotic syndrome: a report of the Southwest Pediatric Nephrology Study Group. J Pediatr. 2003;142:145–8.CrossRefPubMedGoogle Scholar
  86. 86.
    Goldstein SL, Somers MJ, Lande MB, Brewer ED, Jabs KL. Acyclovir prophylaxis of varicella in children with renal disease receiving steroids. Pediatr Nephrol. 2000;14:305–8.CrossRefPubMedGoogle Scholar
  87. 87.
    Trompeter RS, Lloyd BW, Hicks J, White RH, Cameron JS. Long-term outcome for children with minimal-change nephrotic syndrome. Lancet. 1985;1:368–70.CrossRefPubMedGoogle Scholar
  88. 88.
    Wynn SR, Stickler GB, Burke EC. Long-term prognosis for children with nephrotic syndrome. Clin Pediatr (Phila). 1988;27:63–8.CrossRefGoogle Scholar
  89. 89.
    Fakhouri F, Bocquet N, Taupin P, Presne C, Gagnadoux MF, Landais P, Lesavre P, Chauveau D, Knebelmann B, Broyer M, Grünfeld JP, Niaudet P. Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am J Kidney Dis. 2003;41:550–7.CrossRefPubMedGoogle Scholar
  90. 90.
    Rüth EM, Kemper MJ, Leumann EP, Laube GF, Neuhaus TJ. Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr. 2005;147:202–7.CrossRefPubMedGoogle Scholar
  91. 91.
    Ishimori S, Kaito H, Ohtsubo H, Hashimoto F, Ninchoji T, Hashimura Y, Morisada N, Iijima K. Current status and complications of adult patients with childhood-onset steroid-sensitive nephrotic syndrome [in Japanese]. J Jpn Pediatr Soc. 2013;117:90–6.Google Scholar

Copyright information

© Japanese Society of Nephrology and The Japanese Society for Pediatric Nephrology 2015

Authors and Affiliations

  • Yoshitsugu Kaku
    • 1
  • Yasufumi Ohtsuka
    • 2
  • Yasuhiro Komatsu
    • 3
  • Toshiyuki Ohta
    • 4
  • Takuhito Nagai
    • 5
  • Hiroshi Kaito
    • 6
  • Shuji Kondo
    • 7
  • Yohei Ikezumi
    • 8
  • Seiji Tanaka
    • 9
  • Shinsuke Matsumoto
    • 10
  • Mayumi Sako
    • 11
  • Kazushi Tsuruga
    • 12
  • Koichi Nakanishi
    • 13
  • Koichi Kamei
    • 14
  • Hiroshi Saito
    • 15
  • Shuichiro Fujinaga
    • 16
  • Yuko Hamasaki
    • 17
  • Hiroko Chikamoto
    • 18
  • Kenji Ishikura
    • 19
    Email author
  • Kazumoto Iijima
    • 6
  1. 1.Department of NephrologyFukuoka Children’s HospitalFukuokaJapan
  2. 2.Department of Pediatrics, Faculty of MedicineSaga UniversitySagaJapan
  3. 3.Division of Nephrology, Department of MedicineSt. Luke’s International HospitalTokyoJapan
  4. 4.Department of Pediatric NephrologyHiroshima Prefectural HospitalHiroshimaJapan
  5. 5.Department of NephrologyAichi Children’s Health and Medical CenterAichiJapan
  6. 6.Department of PediatricsKobe University Graduate School of MedicineKobeJapan
  7. 7.Department of Pediatrics, Institute of Health BioscienceTokushima UniversityTokushimaJapan
  8. 8.Department of PediatricsNiigata University Medical and Dental HospitalNiigataJapan
  9. 9.Department of Pediatrics and Child HealthKurume University Medical CenterFukuokaJapan
  10. 10.Department of PediatricsMatsudo City Hospital Children’s Medical CenterChibaJapan
  11. 11.Division for Clinical Trials, Department of Development Strategy, Center for Social and Clinical ResearchNational Research Institute for Child Health and DevelopmentTokyoJapan
  12. 12.Department of PediatricsHirosaki University Graduate School of MedicineHirosakiJapan
  13. 13.Department of PediatricsWakayama Medical UniversityWakayamaJapan
  14. 14.Department of Nephrology and RheumatologyNational Center for Child Health and DevelopmentTokyoJapan
  15. 15.Department of PediatricsNihon University School of MedicineTokyoJapan
  16. 16.Division of NephrologySaitama Children’s Medical CenterSaitamaJapan
  17. 17.Department of Pediatric NephrologyToho University Faculty of MedicineTokyoJapan
  18. 18.Department of Pediatric NephrologyTokyo Women’s Medical University, School of MedicineTokyoJapan
  19. 19.Department of NephrologyTokyo Metropolitan Children’s Medical CenterFuchuJapan

Personalised recommendations